Table 3.

Activities and Outcomes of the University of North Carolina Family Medicine Center Controlled Medication Advisory Board, 2015–2018

Number of referrals117
Sources of referrals55 providers made referrals (Range, 1–11 referrals per provider)
Opioid Risk Tool Score*High risk (ORT > 8), 38% (n = 24) Moderate risk (ORT 4–7), 36% (n = 23) Lower risk (ORT < 4), 27% (n = 17)
OutcomesPercent of referrals
Treatment plan revision recommended60% (n = 70/117)
Exemptions to policy approved3% (n = 4/117)
Recommendation to refer to behavioral health provider39% (n = 46/117)
Opioid decrease recommended by CMAB40% (39/98)
 Of these, recommended decrease was successfully achieved64% (25/39)
Benzodiazepine decrease recommended by CMAB20% (20/98)
 Of these, recommended decrease was successfully achieved65% (n = 13/20)
Naloxone was prescribed following recommendation by CMAB review79% (n = 26/33)
Urine screen was conducted within 3 months following CMAB review71% (n = 83/117)
Patient deceased (all were non-opioid deaths due to health conditions or natural causes)5% (n = 6/117)
Patients no longer seen at FMC (of these, 5 [22%] left because they followed their primary care physician when they relocated to a new practice)
20% (n = 23/117)
  • CMAB, controlled medication advisory board; FMC, Family Medicine Center; ORT, Opioid Risk Tool.

  • * Data available for 64 patients, assesses risk of opioid abuse

  • An opioid decrease was only recommended in 39 patients. Most of the other patients fit in the following categories: opioids already appropriately low dose, opioids already in the process of being tapered, or CMAB recommended not restarting opioids.

  • This denominator of 98 is less than 117 because several of our CMAB referrals did not receive full consults due to very specific questions such as urine toxicology screen interpretation or help with referral processes.